Business
Lexaria Provides Update on Material Transfer Agreement With Pharmaceutical Company
KELOWNA, BRITISH COLUMBIA - May 12, 2025 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"KELOWNA, BRITISH COLUMBIA - May 12, 2025 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms, provides this update on corporate developments.\nLexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement (\"MTA\") with a pharmaceutical company (\"PharmaCO\") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.\nLexaria today announces that the initial pre-clinical studies covered by the MTA, which examined pharmacokinetics in animals, have been performed. Results of that work will not be made public. In addition, Lexaria reports being informed by PharmaCO that they wish to review the pending safety (adverse events) and efficacy data from Lexaria's ongoing independent human study GLP-1-H24-4 currently underway in Australia. We expect that data to become available beginning in Q3, 2025.\nLexaria is preparing for strategic planning discussions with PharmaCO's human clinical development team soon given the possibility that potential additional collaborative work may include human clinical studies.\nThe parties have agreed to continue their relationship under the MTA and to keep the temporary exclusive license active and in force until such time as the data from the Australian study becomes available and final decisions have been made, at which time further information will be provided.\nAbout Lexaria Bioscience Corp. & DehydraTECH\nDehydraTECH(TM) is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.\nCAUTION REGARDING FORWARD-LOOKING STATEMENTS\nThis press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as \"anticipate,\" \"if,\" \"believ...